3/19
07:05 pm
ptgx
J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]
Medium
Report
J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]
3/19
04:47 pm
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.
3/19
03:59 pm
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.
3/19
11:47 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.
3/19
10:44 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.
3/18
03:56 pm
ptgx
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript [Seeking Alpha]
Low
Report
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript [Seeking Alpha]
3/18
02:07 pm
ptgx
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/18
02:07 pm
ptgx
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Johnson Rice.
Low
Report
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Johnson Rice.
3/18
08:19 am
ptgx
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis [Yahoo! Finance]
3/18
08:14 am
ptgx
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist [Seeking Alpha]
Medium
Report
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist [Seeking Alpha]
3/12
02:11 pm
ptgx
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
06:18 am
ptgx
ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Low
Report
ADZYNMA (Takeda Pharmaceutical: ADAMTS13, recombinant-krhn) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
3/3
10:18 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.
3/2
02:22 am
ptgx
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]
Low
Report
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]
3/1
01:42 am
ptgx
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
Low
Report
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
2/26
01:36 pm
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
2/26
10:30 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.
2/26
09:55 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a "market outperform" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a "market outperform" rating on the stock.
2/25
04:01 pm
ptgx
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit [Yahoo! Finance]
Low
Report
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit [Yahoo! Finance]
2/18
06:38 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
2/2
05:15 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
2/1
01:05 am
ptgx
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
1/30
07:02 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/7
09:28 pm
ptgx
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
1/7
06:21 pm
ptgx
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
Medium
Report
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]